In a striking policy reversal, Argentina formally lifted their bans on e-cigarettes and heated tobacco products in April-May 2026, joining a growing bloc of nations abandoning prohibition in favour of smart, evidence-based regulation.
For India, still deliberating its own tobacco control framework, the signal is hard to ignore.
Argentina's case is the starkest. After 15 years of an outright ban, Buenos Aires acknowledged the uncomfortable truth: prohibition hadn't reduced consumption, it had simply driven it underground. With no quality controls, no age verification, and no traceability, the black market thrived. The government replaced the ban with comprehensive regulatory architecture: mandatory product registration, strict ingredient disclosure, and a traceability mechanism explicitly designed to block sales to minors. The message from Buenos Aires was blunt- bans don't work; accountability does.
Bangladesh followed suit, implementing parallel controls as it opened its market, signaling that even conservative regulatory environments are pivoting toward managed access over failed prohibition.
The FDA Model Goes Global
The intellectual backbone of this shift is the U.S. Food and Drug Administration's risk-tiered regulatory framework, increasingly seen as the global gold standard over the WHO's blanket prevention approach. The FDA doesn't treat all nicotine products as equivalent. Instead, it differentiates by harm level, subjecting each product to rigorous scientific scrutiny before market access is granted. Of roughly 26 million applications, only 34 smokeless tobacco products have received approval, hardly a free-for-all.
Starting late 2025, the FDA accelerated this framework for next-generation nicotine products, with the Trump administration explicitly backing faster approvals for non-combustible alternatives. White House spokesperson Kush Desai framed it plainly - decisions will be guided by the highest standard of scientific evidence'. Marketing controls- biometric authentication, identity verification, Bluetooth-enabled age locks are baked into approved product categories.
The results on youth protection are striking. Between 2023 and 2024, FDA education campaigns prevented nearly 450,000 adolescents from initiating e-cigarette use. School-age users dropped from 5.38 million in 2019 to 1.63 million in 2024, a near 70% decline, the lowest in over a decade. Minimum purchase age was raised to 21 in 2019; ID checks for under-30s kicked in from 2024.
The WHO-FDA Fault Line
The divergence between the WHO's maximum-prevention doctrine and the FDA's calibrated harm-reduction model is more than academic- it has real trade and fiscal consequences. Countries that mechanically apply WHO guidance risk pushing persistent demand into informal channels, enlarging black markets, draining tax revenues, and paradoxically increasing youth exposure through unregulated products. The WHO's recommendations remain non-binding. The question is whether rigid adherence serves public health goals or undermines them.
What This Means for India
India sits at a crossroads familiar to Argentina not long ago. The 2019 ban on e-cigarettes addressed legitimate youth protection concerns, but enforcement gaps have allowed a shadow market to expand. As India constructs its next regulatory phase, the international evidence increasingly points in one direction: conditional, risk-stratified regulation outperforms prohibition on every measurable outcome- youth access, market transparency, smuggling control, and tax compliance.
"Harm reduction is not a new concept in public health, we use it in infectious disease, in substance use, and in occupational medicine. The question for nicotine policy is whether a risk-stratified regulatory model, with robust age-verification, product registration, and ingredient disclosure, produces better measurable outcomes than prohibition alone. The data from the United States, particularly the near 70% decline in school-age e-cigarette use between 2019 and 2024 under the FDA's structured framework, warrants serious academic attention in India. We should be guided by outcomes, not by the regulatory philosophy we started with," says Dr Chandrakant S Pandav, Former Professor and Head of the Centre for Community Medicine at the All India Institute of Medical Sciences (AIIMS), New Delhi.
"The global evidence is becoming increasingly difficult to set aside. Combustible tobacco remains the single largest preventable cause of lung disease in India, and our primary obligation as clinicians is to reduce that burden by the most effective means available. What the Argentine and FDA data suggest is that blanket prohibition, without a parallel enforcement and traceability infrastructure, can inadvertently consolidate demand into unregulated black markets which, from a clinical standpoint, is arguably a worse outcome than a tightly controlled legal market. India's policymakers would benefit from a careful, evidence-led review of these outcomes before finalising the next phase of our tobacco control framework," says Dr Mohsin Wali, Senior Consultant Physician & Cardiologist, Sir Ganga Ram Hospital, New Delhi.
Argentina didn't abandon health goals. It chose a more effective path to achieve them. India's policymakers would do well to study both the 15-year failure that preceded Argentina's reversal- and the robust framework that replaced it.